John G. Cleland

University Avenue
Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial.

Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial.

Journal: EBioMedicine

Published: February 05, 2026

Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with Both SGLT2i and ARNI.

Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with Both SGLT2i and ARNI.

Journal: Journal of cardiac failure

Published: January 01, 2026

A transformer-based survival model for prediction of all-cause mortality in patients with heart failure: a multi-cohort study.

A transformer-based survival model for prediction of all-cause mortality in patients with heart failure: a multi-cohort study.

Journal: NPJ digital medicine

Published: October 01, 2025

Mechanistic insights into heart failure progression and therapeutic target discovery through plasma microRNA profiling: Findings from HOMAGE.

Mechanistic insights into heart failure progression and therapeutic target discovery through plasma microRNA profiling: Findings from HOMAGE.

Journal: European journal of internal medicine

Published: September 24, 2025

Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.

Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure.

Journal: Heart (British Cardiac Society)

Published: September 02, 2025

Effect of pirfenidone on plasma markers of collagen turnover in patients with heart failure, preserved left ventricular ejection fraction and myocardial fibrosis.

Effect of pirfenidone on plasma markers of collagen turnover in patients with heart failure, preserved left ventricular ejection fraction and myocardial fibrosis.

Journal: Open heart

Published: July 29, 2025

Predicting 30-day mortality after hospital admission for heart failure: the National Heart Failure Audit for England and Wales.

Predicting 30-day mortality after hospital admission for heart failure: the National Heart Failure Audit for England and Wales.

Journal: Heart (British Cardiac Society)

Published: July 24, 2025

Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEinging (HOMAGE) randomized trial.

Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEinging (HOMAGE) randomized trial.

Journal: Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

Published: June 14, 2025

Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial.

Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial.

Journal: Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

Published: June 14, 2025

Patiromer for Patients with Heart Failure at Risk of Hyperkalemia: CARE-HK in HF Registry.

Patiromer for Patients with Heart Failure at Risk of Hyperkalemia: CARE-HK in HF Registry.

Journal: Journal of cardiac failure

Published: May 29, 2025

Patiromer for Patients With Heart Failure at Risk of Hyperkalemia: CARE-HK in HF Registry.

Patiromer for Patients With Heart Failure at Risk of Hyperkalemia: CARE-HK in HF Registry.

Journal: Journal of cardiac failure

Published: May 29, 2025

Commentary on Wittes et al: Aspirin for primary prevention of CV events - Rationally robust? Statistically significant? Clinically convincing?

Commentary on Wittes et al: Aspirin for primary prevention of CV events - Rationally robust? Statistically significant? Clinically convincing?

Journal: Clinical trials (London, England)

Published: April 01, 2025

Showing 1-12 of 182

Last Updated: 09/26/2026